Search
Iopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnIt was developed and filed to the FDA by the company BRACCO. This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada. … On September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082]
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigationalby a reduced number of mature neutrophils and lymphocytes. … [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4.
Synonyms: 1,4-BUTANEDIAMINE, N-(1H-BENZIMIDAZOL-2-YLMETHYL)-N-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-, 1,4-BUTANEDIAMINE, N1-(1H-BENZIMIDAZOL-2-YLMETHYL)-N1-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-Dexpanthenol
go.drugbank.com/drugs/DB09357ApprovedInvestigationalDexpanthenol is also available as a racemic mixture containing both the dextrorotatory form (dexpanthenol) and the levorotatory form (levopanthenol) as [DB11204]. … While pantothenic acid is optically active, only the dextrorotatory form (dexpanthenol) is biologically active.
Synonyms: (2R)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamideProtein C
go.drugbank.com/drugs/DB11312ApprovedInvestigationalIt is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot
Mixtures: Beriplex P/n 500, Beriplex P/n 1000Isoeugenol
go.drugbank.com/drugs/DB14188ApprovedIt is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278].
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalVIII, but does not contain the B-domain, which has no known biological function, and [DB13192], which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. … Haemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency of factor VIII.
Crizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigational[A250785] Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.[L42460] … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement
Glycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalGlycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Ecallantide
go.drugbank.com/drugs/DB05311ApprovedApart from its FDA and EMA indication, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE [A32017]. … It was discovered by phage display technology [A32017].
Threonine
go.drugbank.com/drugs/DB00156ApprovedInvestigationalNutraceuticalAn essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.
Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%